Stockscreener 앱 받기
2.89
2.12%
0.06
시간 외 거래:
2.90
0.010
+0.35%
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Ovid Therapeutics (NASDAQ:OVID) Raised to Hold at Wall Street Zen - marketbeat.com
symbol__ Stock Quote Price and Forecast - CNN
Morgan Stanley (OVID) investor files to sell 150,000 shares valued at $420,000 - Stock Titan
Ovid Therapeutics (OVID) investor reports 9.6M-share beneficial stake - Stock Titan
RA Capital reports 9.99% Ovid Therapeutics stake (OVID) via stock and warrants - Stock Titan
Eventide Asset Management (OVID) discloses 6.3% ownership stake in Ovid Therapeutics - Stock Titan
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Ovid Therapeutics (OVID) sees 4.99% beneficial stake reported by Balyasny group - Stock Titan
Ovid Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
META_TITLE_QUOTE - Yahoo Finance
Affinity Asset Advisors (OVID) discloses 15.1M-share Ovid stake with warrant cap - Stock Titan
Ovid Therapeutics (NASDAQ:OVID) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Ovid Therapeutics (NASDAQ:OVID) Stock Price Up 9% Following Better-Than-Expected Earnings - MarketBeat
Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
OVID: Advanced pipeline, strong cash runway, and soticlestat monetization drive future growth - TradingView
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
OVID: Advanced pipeline, strong cash reserves, and expanded leadership drive long-term growth - TradingView
Ovid Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
OVID Looks 59.6% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
Form 8K Ovid Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Ovid Therapeutics Inc. Q2 2026: Revenue $0.7M, EPS $(0.08) — 10-Q Summary - TradingView
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - The Manila Times
Ovid’s OV329 enters Phase 2 study for treatment-resistant focal seizures - Stock Titan
"Biotech in the Balance"Dr. Jeremy Levin, author and Chair of Ovid Therapeutics - MarketScale
Ovid Therapeutics Inc (OVID) News, Articles, Events & Latest Updates - Stocktwits
Ovid Therapeutics Inc (NASDAQ: OVID) Share Price, OVID Stock News, OVID Share Price & Updates - Kalkine
Ovid Therapeutics Inc. (OVID) stock price, news, quote and history - Yahoo Finance Australia
Ovid Therapeutics Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Ovid Therapeutics Inc (OVID) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline - Yahoo Finance
Ovid Therapeutics (OVID) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
Janus Henderson Group PLC Takes $23.73 Million Position in Ovid Therapeutics $OVID - MarketBeat
Oppenheimer Adjusts Ovid Therapeutics Price Target to $9 From $7, Maintains Outperform Rating - marketscreener.com
Ovid Therapeutics (NASDAQ:OVID) Given New $9.00 Price Target at Oppenheimer - marketbeat.com
Ally Bridge Group NY LLC Has $6.26 Million Position in Ovid Therapeutics $OVID - marketbeat.com
Ovid Therapeutics Inc. Revenue Breakdown – NASDAQ:OVID - TradingView
Ovid Therapeutics Inc (OVID) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ovid Therapeutics Inc (OVID) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ovid Therapeutics Inc (OVID) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ovid Therapeutics Inc (OVID) Income Statement - TradingKey
OVID|Ovid Therapeutics Inc|Price:2.355|Chg%:+0.025 - TradingKey
Ovid Therapeutics Inc (OVID) Institutional Confidence - TradingKey
Ovid Therapeutics Inc (OVID) Balance Sheet - TradingKey
Ovid Therapeutics Inc (OVID) Cash Flow - TradingKey
Ovid Therapeutics Inc (OVID) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ovid Therapeutics Inc. Revenue Breakdown – GETTEX:1OT - TradingView
Ovid Therapeutics Inc (OVID) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OVID|Ovid Therapeutics Inc|Price:2.330|Chg%:-0.070 - TradingKey
Affinity Asset Advisors LLC Acquires 3,486,318 Shares of Ovid Therapeutics $OVID - marketbeat.com
Ovid Therapeutics Inc (OVID) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
This Pharmaceutical Stock is a Top Pick at B. Riley - Investing.com UK
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Nigeria
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com
Ovid Therapeutics (NASDAQ:OVID) Sees Large Increase in Short Interest - MarketBeat
Ovid Therapeutics (OVID) Slips 2.6% as Stock Hovers Near Key Support ZoneGamma Squeeze - dars.gov.et
Ovid Therapeutics (OVID) Edges Higher, Holding Above Key Support ZoneMoving Average Ribbon - dars.gov.et
Ovid Therapeutics (OVID) Edges Higher, Tests Key Resistance Near $2.61Mutual Fund Flow - po-news-eg.net
FEDERATED HERMES, INC. Increases Stake in Ovid Therapeutics Inc - GuruFocus
Ovid Therapeutics names new chief business officer By Investing.com - Investing.com Nigeria
Ovid Therapeutics Appoints New Executives to Drive Strategic Growth - sekbernews.id
Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer - Yahoo Finance
1.80%
1.62%
자본화:
|
볼륨(24시간):